• David J Kuter, James B Bussel, Adrian Newland, Ross I Baker, Roger M Lyons, Jeffrey Wasser, Jean-Francois Viallard, Gail Macik, Mathias Rummel, Kun Nie, and Susie Jun.
• Massachusetts General Hospital, Boston, MA 02114, USA. kuter.david@MGH.harvard.edu
• Br. J. Haematol. 2013 May 1; 161 (3): 411-23.

AbstractRomiplostim was effective, safe, and well-tolerated over 6-12 months of continuous treatment in Phase 3 trials in patients with immune thrombocytopenia (ITP). This report describes up to 5 years of weekly treatment with romiplostim in 292 adult ITP patients in a long-term, single-arm, open-label study. Outcome measures included adverse events (including bleeding, thrombosis, malignancy, and reticulin/fibrosis), platelet response (platelet count >50 × 10(9) per litre), and the proportion of patients requiring rescue treatments. Treatment-related serious adverse events were infrequent and did not increase with longer treatment. No new classes of adverse events emerged. Thrombotic events occurred in 6.5% of patients and were not associated with platelet count. Median platelet counts of 50-200 × 10(9) per litre were maintained with stable doses of romiplostim (mean 5-8 μg/kg; generally self-administered at home) throughout the study. A platelet response was achieved at least once by 95% of patients, with a platelet response maintained by all patients on a median 92% of study visits. There was a low rate of bleeding and infrequent need for rescue treatments. In conclusion, this study demonstrated that romiplostim was safe and well-tolerated over 614 patient-years of exposure in ITP patients, and that efficacy was maintained with stable dosing for up to 5 years of continuous treatment.© 2013 Blackwell Publishing Ltd.

38 keywords...

hide…